SG182490A1 - Methods of producing adenovirus vectors and viral preparations generated thereby - Google Patents

Methods of producing adenovirus vectors and viral preparations generated thereby Download PDF

Info

Publication number
SG182490A1
SG182490A1 SG2012051496A SG2012051496A SG182490A1 SG 182490 A1 SG182490 A1 SG 182490A1 SG 2012051496 A SG2012051496 A SG 2012051496A SG 2012051496 A SG2012051496 A SG 2012051496A SG 182490 A1 SG182490 A1 SG 182490A1
Authority
SG
Singapore
Prior art keywords
seq
set forth
wild type
adenovirus
polynucleotide
Prior art date
Application number
SG2012051496A
Other languages
English (en)
Inventor
Livnat Bangio
Naamit Sher
Eyal Breitbart
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of SG182490A1 publication Critical patent/SG182490A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG2012051496A 2010-01-12 2011-01-12 Methods of producing adenovirus vectors and viral preparations generated thereby SG182490A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29415810P 2010-01-12 2010-01-12
PCT/IB2011/050137 WO2011086509A1 (en) 2010-01-12 2011-01-12 Methods of producing adenovirus vectors and viral preparations generated thereby

Publications (1)

Publication Number Publication Date
SG182490A1 true SG182490A1 (en) 2012-08-30

Family

ID=43982270

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201500015TA SG10201500015TA (en) 2010-01-12 2011-01-12 Methods of producing adenovirus vectors and viral preparations generated thereby
SG2012051496A SG182490A1 (en) 2010-01-12 2011-01-12 Methods of producing adenovirus vectors and viral preparations generated thereby

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201500015TA SG10201500015TA (en) 2010-01-12 2011-01-12 Methods of producing adenovirus vectors and viral preparations generated thereby

Country Status (6)

Country Link
US (2) US20130052165A1 (enExample)
EP (1) EP2523681A1 (enExample)
JP (1) JP6009357B2 (enExample)
IL (1) IL220922B (enExample)
SG (2) SG10201500015TA (enExample)
WO (1) WO2011086509A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
NZ532348A (en) 2001-10-19 2006-06-30 Vascular Biogenics Ltd Polynucleotide constructs comprising ligand binding domains, effector domains of apoptosis signaling molecules and a promoter or enhancer and their use in gene therapy
JP5513885B2 (ja) 2006-07-31 2014-06-04 ヴァスキュラー バイオジェニックス リミテッド ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用
JP6151515B2 (ja) 2010-01-05 2017-06-21 バスキュラー バイオジェニックス リミテッド 神経膠芽腫ｇｂｍを治療するための組成物および方法
US9567605B2 (en) 2010-01-05 2017-02-14 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
SI2908865T1 (sl) * 2012-10-17 2019-02-28 Vascular Biogenics Ltd. Adenovirus, ki izraža Fas himero in uporaba le-tega v postopkih zdravljenja raka
CN103012591B (zh) * 2012-12-12 2014-05-14 武汉吉爱生物技术有限公司 抗Benzonase单克隆抗体、其制备方法和应用
WO2014118643A2 (en) 2013-02-04 2014-08-07 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
BR112015022292A2 (pt) * 2013-03-15 2017-07-18 Childrens Hospital Philadelphia processo de fabricação escalonável para produzir vetores lentivirais recombinantes em um sistema de cultura celular em suspensão sem soro
CN107603956A (zh) * 2017-08-24 2018-01-19 乾元浩生物股份有限公司 一种禽腺病毒纸片载体潮汐式悬浮培养方法
CN107630004B (zh) * 2017-09-01 2021-01-15 康希诺生物股份公司 降低可复制性腺病毒产生的细胞株及构建方法和应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5747340A (en) 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
EP1707631A3 (en) * 1996-11-20 2006-12-27 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
AU779267B2 (en) * 1998-12-31 2005-01-13 Centelion S.A.S. Method for separating viral particles
US6168941B1 (en) * 2000-04-07 2001-01-02 Genvec, Inc. Method of producing adenoviral vector stocks
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2002348151A1 (en) * 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
US7459154B2 (en) * 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
WO2006079176A1 (en) * 2005-01-28 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
JP5513885B2 (ja) 2006-07-31 2014-06-04 ヴァスキュラー バイオジェニックス リミテッド ポリペプチド、および、当該ポリペプチドをコードするポリヌクレオチド、および、虚血に関連する医学的状態の治療におけるそれらの使用

Also Published As

Publication number Publication date
WO2011086509A1 (en) 2011-07-21
IL220922B (en) 2019-03-31
JP6009357B2 (ja) 2016-10-19
US20130295053A1 (en) 2013-11-07
EP2523681A1 (en) 2012-11-21
JP2013516978A (ja) 2013-05-16
SG10201500015TA (en) 2015-02-27
US20130052165A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
US20130295053A1 (en) Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby
ES2246533T3 (es) Fibra adenovirica modificada y adenovirus dianas.
AU2005250396B2 (en) Chimeric adenoviruses for use in cancer treatment
ZA200406942B (en) Means and methods for the production of adenovirus vectors
JP2008501349A (ja) 腫瘍溶解性アデノウイルス組換え体、特に、腫瘍において免疫調節因子ｇｍ−ｃｓｆを発現する組換え体の構築およびその利用
JP2000201673A (ja) 非エンベロ―プウイルスのウイルス調製物におけるエンベロ―プウイルスの不活性化法
US20110189234A1 (en) Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles
KR20130015270A (ko) 종양 특이적 프로모터 및 이를 포함하는 종양살상 바이러스 벡터
JP2002330786A (ja) 抗炎症性ベクター
Li et al. E1A-engineered human umbilical cord mesenchymal stem cells as carriers and amplifiers for adenovirus suppress hepatocarcinoma in mice
AU752148B2 (en) Chimeric adenoviral vectors
JP2002512785A (ja) 疾患治療用のアデノウイルスベクター
US20220235332A1 (en) Fast and Accurate Three-Plasmid Oncolytic Adenovirus Recombinant Packaging System AD5MIXPLUS and Application Thereof
EP4048798B1 (en) Adenovirus comprising a modified adenovirus hexon protein
AU775717B2 (en) Use of specific hybrid promoters for controlling tissue expression
CN101538556B (zh) 腺病毒选择性互补复制的方法
Wienen Development and characterization of oncolytic adenoviral vectors for the treatment of head and neck cancer
TWI391486B (zh) 新穎啟動子及包含其之病毒載體
RU2194755C2 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pAd5-f, НЕСУЩАЯ ФРАГМЕНТ ГЕНОМА АДЕНОВИРУСА 5 ТИПА С ДЕЛЕЦИЕЙ В ГЕНЕ E1B-55K, И ШТАММ МУТАНТНОГО АДЕНОВИРУСА Ade12, ОБЛАДАЮЩИЙ СЕЛЕКТИВНОЙ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
HK1154625B (en) A novel promoter and viral vector containing the same
HK1154625A1 (en) A novel promoter and viral vector containing the same
MXPA01003065A (en) Use of specific hybrid promoters for controlling tissue expression